How to transfer my Mounjaro prescription to California

The rising popularity of medications like Wegovy, Ozempic, and Mounjaro has transformed weight loss treatment—and telehealth has made accessing these medications easier than ever. But with varying state laws and evolving federal regulations, many people wonder: Can I legally get GLP-1 weight loss medications through telehealth?

The short answer: Yes. In most states, you can receive a prescription for weight loss medications like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro) through a legitimate telehealth consultation—no in-person visit required. However, the specific rules depend on where you live, and understanding these requirements can help you access safe, effective treatment while avoiding potential pitfalls.

Understanding the Federal Framework for Telehealth Prescribing

Why GLP-1 Medications Are Different

Unlike controlled substances such as Adderall or pain medications, GLP-1 agonists are not scheduled drugs under federal law. This is crucial because the Ryan Haight Act—which typically requires an in-person exam before prescribing controlled substances via telehealth—doesn’t apply to medications like Wegovy, Ozempic, or Mounjaro.

What this means for you: Federal law places no blanket restriction on prescribing these weight loss medications through telehealth. A licensed provider can evaluate you via video consultation and send your prescription electronically to a pharmacy, as long as they establish a valid patient-provider relationship and you meet medical eligibility criteria.

The Current Regulatory Landscape

During the COVID-19 pandemic, the DEA relaxed prescribing rules for all medications, including controlled substances. While those temporary flexibilities for controlled drugs have been extended multiple times—most recently through December 31, 2025—they never directly affected GLP-1 weight loss medications, which remained fully accessible via telehealth throughout.

As of December 2025, the telehealth landscape has stabilized. The federal government continues to signal support for expanded telemedicine access, with pending legislation like the TREATS Act potentially making some flexibilities permanent. For patients seeking weight loss treatment, this means telehealth options are not only available but likely to improve in the coming years.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-by-State Requirements: What You Need to Know

While federal law permits telehealth prescribing of GLP-1 medications, individual states can impose additional requirements. Some states require initial in-person exams, periodic follow-ups, or specific documentation before prescribing weight loss drugs via telemedicine.

States with No In-Person Requirement

California, Connecticut, Illinois, New York, Pennsylvania, and Washington have no state-mandated in-person visit requirement for GLP-1 prescriptions. In these states, a comprehensive telehealth evaluation—including medical history, current medications, weight and health goals—is sufficient to establish care and receive a prescription if you qualify medically.

States Requiring an Initial In-Person Exam

Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, Texas, Utah, and Virginia require or strongly encourage an initial in-person physical examination before prescribing weight loss medications via telehealth.

For example:

• New Jersey mandates a comprehensive initial evaluation including physical exam, laboratory work, and psychological screening before any weight-loss drug prescription
• Virginia requires baseline labs, a personalized diet and exercise plan, and a follow-up visit within 30 days of starting therapy
• Texas generally expects an in-person exam as part of establishing the standard of care for obesity treatment

These requirements don’t prohibit telehealth—they simply add one extra step. Many telehealth providers work with local clinics or mobile health services to arrange initial exams in these states, after which ongoing care can continue virtually.

States with Ongoing Monitoring Requirements

Florida takes a unique approach: while no initial in-person visit is required, state law mandates patients have a BMI of 30 or higher and be seen (in-person or via telehealth) at least once every three months during treatment. This ensures continuous medical oversight and monitoring for side effects.

Similarly, Connecticut requires providers to include behavioral counseling and a documented diet and exercise plan as part of any obesity treatment—whether delivered in person or via telehealth.

Who Can Prescribe Weight Loss Medications via Telehealth?

Physicians (MDs and DOs)

All states permit licensed physicians to prescribe GLP-1 weight loss medications through telehealth, provided they hold an active license in the state where the patient is physically located during the consultation.

Nurse Practitioners and Physician Assistants

The prescribing authority for Nurse Practitioners (NPs) and Physician Assistants (PAs) varies significantly by state:

Full Independent Practice (No Physician Oversight Required):

• California, Connecticut, Delaware, New York, Utah, Virginia, Washington
• In these states, experienced NPs can prescribe weight loss medications independently after meeting practice hour requirements

Collaborative Practice (Physician Agreement Required):

• Arkansas, Florida, Georgia, Illinois, Mississippi, New Jersey, North Dakota, Pennsylvania, South Carolina, Texas
• NPs and PAs can prescribe GLP-1 medications but must work under a physician collaboration agreement or supervisory protocol

Recent Expansions:Georgia recently authorized NPs and PAs to prescribe even Schedule II controlled substances with physician delegation (effective July 2024)—a significant expansion that demonstrates growing trust in advanced practice providers.

Important note: Klarity Health works exclusively with licensed, credentialed providers operating within their state’s legal scope of practice, so you can feel confident your prescriber is fully authorized to treat you.

Medical Eligibility: Who Qualifies for GLP-1 Weight Loss Medications?

Reputable telehealth services don’t hand out prescriptions indiscriminately. To receive Wegovy, Ozempic (off-label for weight loss), or Mounjaro through telehealth, you typically must meet specific clinical criteria:

Standard Eligibility Requirements

• BMI ≥ 30 (obesity), or
• BMI ≥ 27 with at least one weight-related health condition (such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea)
• Age 18 or older (pediatric use requires additional evaluation)
• Documented attempt at lifestyle modifications (diet and exercise), unless medically inadvisable
• No contraindications (see below)

Medical Contraindications

You will likely be disqualified from GLP-1 therapy if you have:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—these medications carry an FDA boxed warning for thyroid tumors
• Pregnancy or planning to become pregnant (must discontinue at least 2 months before conception)
• Active pancreatitis or history of severe pancreatitis
• Severe gastroparesis or gastrointestinal disorders
• Active gallbladder disease
• History of suicidal ideation (some GLP-1s carry warnings about mental health side effects)

What to Expect During Your Telehealth Evaluation

A legitimate telehealth consultation for weight loss medication will include:

1. Comprehensive Medical Questionnaire: Detailed health history, current medications, allergies, prior weight loss attempts, and mental health screening
2. Live Video Consultation: Real-time discussion with a licensed provider to review your goals, assess eligibility, discuss risks and benefits, and answer questions
3. Weight and Vital Signs Verification: Self-reported (or verified via connected devices/local lab partner)
4. Lab Work Review: Some providers require baseline metabolic panel, thyroid function tests, or A1C before prescribing
5. Informed Consent: Documentation of understanding regarding potential side effects (nausea, vomiting, diarrhea, constipation, gallstones), injection technique, and the importance of lifestyle changes
6. Treatment Plan: Prescription with titration schedule, plus personalized diet and exercise recommendations

The Treatment Process: What Happens After Your Consultation

Prescription and Fulfillment

If approved, your provider will electronically send your prescription to a licensed pharmacy. Most states now require e-prescribing for all medications, which enhances safety and prevents fraud.

Initial prescriptions typically cover:

• 4 weeks (to assess tolerance and side effects)
• Starting dose with gradual titration schedule
• Patient education materials and injection training resources

Ongoing prescriptions may extend to:

• 1-3 months at a time once you’re on a stable, effective dose
• Refills authorized for up to 6-12 months, depending on state law and clinical appropriateness
• Regular check-ins (monthly or quarterly) to monitor progress and adjust treatment

Monitoring and Follow-Up

Unlike older ‘diet pills’ that could be dispensed with minimal oversight, GLP-1 medications require ongoing medical supervision:

• First month: Follow-up within 2-4 weeks to assess tolerance, review side effects, and adjust dosing
• Ongoing: Check-ins every 1-3 months (varies by state—Florida mandates at least quarterly visits)
• Lab monitoring: Periodic metabolic panels, kidney function tests, or thyroid screening as clinically indicated
• Weight tracking: Regular weigh-ins and BMI calculations to measure progress
• Safety monitoring: Assessment for gallbladder symptoms, pancreatitis signs, or mental health changes

Many telehealth platforms, including Klarity Health, provide seamless scheduling for video follow-ups, secure messaging with your provider, and digital tools to track your progress—making ongoing care convenient without sacrificing quality.

Cost Considerations: Insurance vs. Cash Pay

Insurance Coverage

Insurance coverage for GLP-1 weight loss medications varies widely:

• Medicare: Generally does not cover weight loss medications (though Medicare Part D covers diabetes versions like Ozempic for diabetes treatment)
• Medicaid: Coverage varies by state; some states cover Wegovy for obesity, others don’t
• Commercial Insurance: Many plans now cover Wegovy or other GLP-1s for obesity, but often with prior authorization requirements, step therapy (trying other weight loss methods first), or high copays ($25-$500+ per month)

Telehealth implications: Most insurers cover telehealth consultations at the same rate as in-person visits. However, some plans may not cover the medication itself when prescribed via telehealth—always verify with your insurance before starting treatment.

Cash-Pay Telehealth Options

For patients without insurance coverage—or those seeking faster access—many telehealth providers offer cash-pay programs:

• Consultation fees: Typically $50-$200 for initial visit, $40-$100 for follow-ups
• Medication costs: $200-$1,300+ per month out-of-pocket for brand-name drugs like Wegovy (varies by dose and pharmacy)
• Compounded alternatives: Note: As of May 2025, the FDA has banned most compounded semaglutide for weight loss due to safety concerns and the end of drug shortages. Be extremely cautious of any provider offering compounded versions—legitimate pharmacies cannot legally provide them except in very narrow circumstances.

Klarity Health accepts both insurance and cash pay, offering transparent pricing and helping you find the most affordable option for your situation. Our providers can also work with you to explore manufacturer savings programs or patient assistance when available.

Red Flags: How to Avoid Telehealth Scams

The popularity of GLP-1 weight loss drugs has unfortunately attracted some unscrupulous operators. Protect yourself by watching for these warning signs:

🚩 Guaranteed Prescriptions Without Evaluation

Legitimate providers never guarantee you’ll receive a prescription before evaluating your medical history. If a service promises ‘instant approval’ or skips the medical questionnaire, walk away.

🚩 Selling Compounded or ‘Generic’ Semaglutide

As of 2025, the FDA has ended the shortage that previously allowed compounding of semaglutide. Any telehealth service offering compounded semaglutide is likely operating outside federal guidelines and may be providing untested, potentially unsafe products.

🚩 No Follow-Up or Monitoring

Weight loss medications require ongoing medical supervision. Services that prescribe without scheduling follow-up visits or monitoring your progress prioritize profit over patient safety.

🚩 Unclear Provider Credentials

You should always know who your prescriber is, what state they’re licensed in, and their credentials. Be wary of services that don’t clearly identify providers or use ‘medical teams’ without specifying individual qualifications.

🚩 Overseas or Unlicensed Pharmacies

Your prescription should be filled by a U.S.-licensed pharmacy. Services offering to ship medication from overseas or from unlicensed sources may be providing counterfeit products.

🚩 Minimal Medical Screening

Responsible providers screen for contraindications like thyroid cancer history, pregnancy, pancreatitis, and mental health concerns. If the intake process feels rushed or superficial, that’s a red flag.

What to look for instead:

• Detailed medical intake process
• Live video consultation with a licensed provider
• Clear information about provider credentials and state licensure
• Prescriptions sent to legitimate U.S. pharmacies
• Scheduled follow-up appointments
• Transparent pricing and no hidden fees
• Discussion of risks, benefits, and alternatives

Privacy and Data Security in Telehealth Weight Loss Treatment

Weight loss is a sensitive topic, and your medical information deserves protection. When choosing a telehealth provider, verify they comply with federal and state privacy laws:

HIPAA Compliance

All legitimate telehealth platforms must comply with the Health Insurance Portability and Accountability Act (HIPAA), which protects the privacy and security of your health information. This includes:

• Encrypted video consultations
• Secure messaging systems
• Protected electronic health records
• Staff training on privacy practices
• Business associate agreements with third-party vendors

State Consumer Privacy Laws

Several states have enacted additional privacy protections:

• Washington’s My Health My Data Act (effective 2023) imposes strict requirements on health data collection, use, and sharing—including telehealth weight loss services
• California’s CCPA/CPRA gives consumers rights over personal data, including health information
• Similar laws in Connecticut, Virginia, Colorado, and other states

What this means for you: Choose telehealth providers that clearly explain how they collect, use, and protect your data. Klarity Health maintains comprehensive privacy practices aligned with both federal HIPAA requirements and state-specific consumer protection laws.

The Future of Telehealth Weight Loss Treatment

Regulatory Outlook

The trajectory is clear: telehealth access for weight loss treatment will continue to expand. Several factors point to increased availability:

1. Federal Support: The DEA’s repeated extensions of telehealth flexibilities (most recently through December 31, 2025) demonstrate federal commitment to telemedicine access

2. Pending Legislation: The TREATS Act and similar bills in Congress aim to make permanent some telehealth prescribing flexibilities, particularly for chronic disease management

3. State Modernization: More states are joining interstate licensure compacts, making it easier for providers to treat patients across state lines

4. Clinical Evidence: Studies consistently show telehealth weight management programs achieve outcomes comparable to in-person care, with higher patient satisfaction and better adherence

5. Provider Expansion: The growing number of states granting full practice authority to Nurse Practitioners (now 34 states plus DC) increases the provider pool for telehealth obesity care

What to Watch in 2026

• DEA Final Rule: The agency is expected to issue permanent regulations on telehealth prescribing—likely maintaining some level of flexibility given strong public support
• State NP Practice Laws: Several states (Mississippi, Pennsylvania, others) have pending legislation to grant Nurse Practitioners independent practice authority
• Insurance Coverage: As GLP-1 medications demonstrate long-term health benefits, more insurers may expand coverage for weight loss indications
• New Medications: Additional obesity treatments in the pipeline may offer more options, potentially at different price points

How Klarity Health Makes Weight Loss Treatment Accessible

At Klarity Health, we’ve designed our telehealth weight management program with both convenience and safety in mind:

Provider Availability

Our network includes licensed physicians and nurse practitioners across multiple states, ensuring you can connect with a qualified provider regardless of where you live. All providers are credentialed, experienced in obesity medicine, and operate within their state’s legal scope of practice.

Transparent Pricing

We accept both insurance and cash pay, with upfront pricing and no hidden fees. Our care coordinators help you understand costs before you commit to treatment, and we can verify insurance benefits in advance.

Comprehensive Care Model

Your Klarity provider doesn’t just write a prescription—they partner with you for long-term success:

• Thorough initial evaluation (medical history, medications, contraindications screening)
• Personalized treatment plan including medication, diet, and exercise guidance
• Regular follow-up visits (video or phone) to monitor progress and adjust treatment
• Responsive support between appointments via secure messaging
• Coordination with your primary care provider when appropriate

Medication Access

We work with licensed U.S. pharmacies to ensure you receive FDA-approved, brand-name medications. We’ll help you navigate insurance coverage, manufacturer savings programs, and alternative options if cost is a barrier.

Privacy and Security

Your medical information is protected by industry-leading security measures, HIPAA-compliant systems, and transparent privacy practices. Your weight loss journey is personal—we keep it that way.

Taking the Next Step

If you’ve been considering weight loss medication but weren’t sure about the telehealth option, the evidence is clear: legitimate telehealth prescribing of GLP-1 medications is legal, safe, and effective in most states.

The key is choosing a provider that prioritizes your health over quick profits—one that conducts thorough evaluations, provides ongoing monitoring, and operates transparently within state and federal regulations.

Is Telehealth Weight Loss Treatment Right for You?

Consider telehealth if:

• You meet the medical criteria (BMI ≥30 or ≥27 with health conditions)
• You’ve struggled with traditional diet and exercise alone
• In-person appointments are challenging due to schedule, mobility, or location
• You want ongoing support from medical professionals specializing in weight management
• You’re looking for transparent pricing and flexible payment options

Telehealth may not be ideal if:

• Your state requires initial in-person exams and you prefer starting treatment immediately (though many states allow virtual-first care)
• You have complex medical needs requiring hands-on physical examination
• You’re uncomfortable with video consultations
• You don’t have reliable internet access

Ready to Start Your Weight Loss Journey?

At Klarity Health, we’re committed to making evidence-based weight loss treatment accessible, affordable, and personalized. Our providers are available in multiple states, accept both insurance and cash pay, and offer the flexibility of telehealth without compromising on quality care.

Schedule your confidential consultation today to discuss whether GLP-1 weight loss medications are right for you. Our providers will conduct a comprehensive evaluation, answer all your questions, and create a personalized plan to help you achieve sustainable weight loss.

Frequently Asked Questions

Q: Do I need to visit a doctor in person before getting a telehealth prescription for Wegovy or Ozempic?

A: It depends on your state. Federal law doesn’t require an in-person visit for these medications (they’re not controlled substances), but about 10 states do mandate an initial physical exam before prescribing weight loss drugs. Check the state-specific table in this guide, or ask when you schedule your consultation—reputable providers like Klarity will clarify your state’s requirements upfront.

Q: Can nurse practitioners prescribe weight loss medications through telehealth?

A: Yes, in all 50 states—though the level of independence varies. In states with full practice authority (like California, New York, Washington), NPs can prescribe independently. In others (like Texas, Florida, Pennsylvania), they need a physician collaboration agreement. Either way, NPs are fully qualified to manage weight loss treatment, and many telehealth platforms primarily use NPs for obesity care.

Q: Will my insurance cover telehealth weight loss medication?

A: Many insurance plans now cover GLP-1 medications like Wegovy for obesity, but coverage varies widely. Some require prior authorization, documentation of failed diet attempts, or impose high copays. Most insurers cover telehealth consultations at the same rate as office visits. Contact your insurance or ask your telehealth provider to verify benefits before starting treatment.

Q: Is it safe to get weight loss medication online without seeing a doctor face-to-face?

A: Yes—when done correctly. Legitimate telehealth platforms conduct thorough evaluations (medical history, medications, contraindications screening) via video consultation, which research shows is as effective as in-person care for weight management. The key is choosing a reputable provider that requires live video visits, licensed prescribers, and ongoing monitoring—not just a questionnaire and auto-prescription.

Q: How long does it take to get a prescription through telehealth?

A: With most telehealth services, you can complete your consultation within 24-48 hours of requesting an appointment. If approved, your prescription is sent electronically to a pharmacy the same day. Total time from initial contact to picking up medication is typically 2-5 days, depending on pharmacy stock and your schedule.

Q: What if I move to a different state while on treatment?

A: Your provider must be licensed in the state where you physically reside at the time of each consultation. If you move, you’ll need to transfer care to a provider licensed in your new state. Many multi-state telehealth platforms (like Klarity) can facilitate this transition seamlessly by connecting you with a new provider in their network.

📅 RESEARCH CURRENCY STATEMENT
Verified as of: December 17, 2025
DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.
States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of Dec 2025)
Sources newer than 2024: 15 of 18 sources (most sources are 2024–2025; older sources used only for baseline context)

⚠️ Note: Federal telehealth rules for controlled substances are temporary (set to expire 12/31/2025) – an additional extension or new rule is expected. State laws are constantly evolving; watch for any changes in 2026. FDA oversight on compounded GLP-1 medications tightened in 2025 – ensure compliance with current FDA guidance.

Citations and Sources

1. U.S. Drug Enforcement Administration (DEA) – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (November 15, 2024). Official announcement confirming extension of telehealth prescribing flexibilities through December 31, 2025. Available at: www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Axios – ‘COVID-era telehealth prescribing extended’ (November 18, 2024). News report on DEA’s third extension of pandemic-era telehealth flexibility for controlled substances, providing context on federal telemedicine policy. Available at: www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

3. McDermott Will & Emery LLP – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ (November 18, 2024). Legal analysis explaining the Ryan Haight Act exemptions and current telehealth prescribing rules, including clarification that non-controlled medications are not subject to in-person requirements. Available at: www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025

4. Goodwin Procter LLP – ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (March 27, 2024). Comprehensive legal alert detailing state-specific requirements for prescribing weight loss medications, including Florida’s 3-month follow-up rule, New Jersey’s comprehensive evaluation requirements, and Virginia’s initial exam mandates. Available at: www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. Reuters – ‘Hims to cut 4% of workforce amid ban on weight-loss drug copies’ (May 30, 2025). News report on FDA’s enforcement action ending the compounding of semaglutide for weight loss, demonstrating current regulatory oversight of telehealth GLP-1 prescribing practices. Available at: www.reuters.com/business/healthcare-pharmaceuticals/hims-cut-4-workforce-amid-ban-weight-loss-drug-copies-2025-05-30

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid